Medical device company Nevro Corp. (NYSE: NVRO), that specialises in chronic pain treatment, on Monday released new data showcasing the cost-effectiveness of its proprietary 10 kHz Therapy, a high-frequency spinal cord stimulation (SCS) therapy. The data, based on health care utilization (HCU) assessments, reveal substantial reductions in hospital resource usage associated with 10 kHz Therapy for treating Painful Diabetic Neuropathy (PDN) and nonsurgical refractory back pain.

In a study published in the Journal of Managed Care & Specialty Pharmacy, patients receiving 10 kHz Therapy for PDN demonstrated half the hospitalisation rate compared to conventional medical management (CMM), resulting in 51% lower healthcare costs per patient.

Another analysis, published in the Journal of Neurosurgery: Spine, assessed the cost-effectiveness of 10 kHz Therapy for nonsurgical refractory back pain patients, showing that it provides a higher quality of life at a lower average cost per patient compared to CMM therapy. Cost-effectiveness is predicted within 2.1 years.

A third study, published in Neuromodulation, examined the cost impact of 10 kHz Therapy for Chronic Refractory Low Back Pain patients. The analysis indicated a significant reduction in total healthcare costs, offsetting device acquisition expenses within 27 months.

Furthermore, data published in the Journal of Diabetes Science and Technology illustrated that 10 kHz Therapy substantially decreases healthcare utilization in PDN patients.

PDN is a progressive, chronic neuropathic pain condition affecting 20% of diabetes patients. In the US, approximately 140,000 to 200,000 PDN patients annually, refractory to conventional medical management, represent a market opportunity of USD3.5bn to USD5.0bn.

Headquartered in Redwood City, California, Nevro's 10 kHz Therapy has impacted over 100,000 patients worldwide. The company's comprehensive HFX spinal cord stimulation (SCS) platform includes the Senza SCS system and support services for trunk and limb chronic pain and painful diabetic neuropathy treatment. Senza, Senza II, Senza Omnia, and HFX iQ are the only SCS systems delivering Nevro's proprietary 10 kHz Therapy. HFX Coach and HFX Cloud provide personalised patient support and enhanced practice management insights for physicians.